Senate
File
470
-
Introduced
SENATE
FILE
470
BY
COMMITTEE
ON
HUMAN
RESOURCES
(SUCCESSOR
TO
SF
282)
(COMPANION
TO
HF
520
BY
COMMITTEE
ON
PUBLIC
SAFETY)
A
BILL
FOR
An
Act
relating
to
the
medical
use
of
cannabidiol
including
the
1
scheduling
of
a
cannabidiol
investigational
product
approved
2
as
a
prescription
drug
medication
under
federal
law
and
3
including
effective
date
provisions.
4
BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
5
TLSB
2301SV
(3)
87
rh/rj
S.F.
470
Section
1.
NEW
SECTION
.
124.201A
Cannabidiol
1
investigational
product
——
rules.
2
1.
If
a
cannabidiol
investigational
product
approved
as
3
a
prescription
drug
medication
by
the
United
States
food
and
4
drug
administration
is
eliminated
from
or
revised
in
the
5
federal
schedule
of
controlled
substances
by
the
federal
drug
6
enforcement
agency
and
notice
of
the
elimination
or
revision
7
is
given
to
the
board,
the
board
shall
similarly
eliminate
8
or
revise
the
prescription
drug
medication
in
the
schedule
9
of
controlled
substances
under
this
chapter.
Such
action
by
10
the
board
shall
be
immediately
effective
upon
the
date
of
11
publication
of
the
final
regulation
containing
the
elimination
12
or
revision
in
the
federal
register.
13
2.
The
board
shall
adopt
rules
pursuant
to
chapter
17A
14
to
administer
this
section.
The
board
may
adopt
rules
on
an
15
emergency
basis
as
provided
in
section
17A.4,
subsection
3,
and
16
section
17A.5,
subsection
2,
to
administer
this
section,
and
17
the
rules
shall
be
effective
immediately
upon
filing
unless
18
a
later
date
is
specified
in
the
rules.
Any
emergency
rules
19
adopted
in
accordance
with
this
section
shall
also
be
published
20
as
a
notice
of
intended
action
as
provided
in
section
17A.4,
21
subsection
1.
22
Sec.
2.
REPEAL.
Section
124D.8,
Code
2017,
is
repealed.
23
Sec.
3.
EFFECTIVE
DATE.
The
section
of
this
Act
repealing
24
section
124D.8,
Code
2017,
takes
effect
June
30,
2017.
25
EXPLANATION
26
The
inclusion
of
this
explanation
does
not
constitute
agreement
with
27
the
explanation’s
substance
by
the
members
of
the
general
assembly.
28
This
bill
relates
to
the
medical
use
of
cannabidiol,
29
including
the
scheduling
of
a
cannabidiol
investigational
30
product
approved
as
a
prescription
drug
medication
under
31
federal
law.
32
The
bill
provides
if
a
cannabidiol
investigational
product
33
approved
as
a
prescription
drug
medication
by
the
United
States
34
food
and
drug
administration
is
eliminated
from
or
revised
in
35
-1-
LSB
2301SV
(3)
87
rh/rj
1/
2
S.F.
470
the
federal
schedule
of
controlled
substances
by
the
federal
1
drug
enforcement
agency
and
notice
of
the
elimination
or
2
revision
is
given
to
the
board,
the
board
of
pharmacy
shall
3
similarly
eliminate
or
revise
the
prescription
drug
medication
4
in
the
schedule
of
controlled
substances
under
Code
chapter
5
124.
Such
action
by
the
board
shall
be
immediately
effective
6
upon
the
date
of
publication
of
the
final
regulation
containing
7
the
elimination
or
revision
in
the
federal
register.
8
The
bill
provides
that
the
board
shall
adopt
rules
pursuant
9
to
Code
chapter
17A
to
administer
the
bill
and
may
adopt
10
emergency
rules
which
shall
be
effective
immediately
upon
11
filing
unless
a
later
date
is
specified
in
the
rules.
Any
12
emergency
rules
adopted
shall
also
be
published
as
a
notice
of
13
intended
action
as
provided
in
Code
section
17A.4,
subsection
14
1.
15
The
bill
strikes
the
repeal
of
Code
chapter
124D
(medical
16
cannabidiol
Act)
before
the
repeal
becomes
effective
July
1,
17
2017.
18
-2-
LSB
2301SV
(3)
87
rh/rj
2/
2